|
Volume 15, Issue 10, October 2008, in PDF
|
   |
Article: 570
IMI and ECRIN Removing Bottlenecks of Drug Development in EU
The Innovative Medicine Initiative (IMI) and the European Clinical Research Infrastructure Network (ECRIN) overall goal is to remove the major bottlenecks in drug development where research is key.
Article: 571
Trio of Companies in Strategic Outsourcing Partnerships with Lilly
Eli Lilly’s recent agreement to sell an R&D facility to Covance is the largest and most comprehensive outsourcing deal in the CRO industry.Somewhat lost in the hoopla around the mega-Lilly-Covance deal, was that Lilly also cut similar agreements at the same time with Quintiles and i3 Statprobe.
Article: 572
Replacing Declaration of Helsinkiwith GCP for Foreign Trials
The Good Clinical Practice (GCP) Guideline of the International Conference on Harmonisation is considered final guidance by FDA. Final guidance is considered a reflection of FDA’s current thinking on a subject.
Article: 573
Eye On: Breast Cancer
Breast cancer, which is the most common cancer among women worldwide, arises from breast tissues, typically from the ducts carrying milk to the nipple or the lobules that secrete milk.Although it occurs in both sexes, it is rare in men.
Price: $59.00
|
